Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.
Kamande JW et al. Integr Biol (Camb). 2018 Jan 26. doi: 10.1039/c7ib00183e. [Epub ahead of print].
Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.
Wang H et al. Oncotarget. 2017 Dec 7;8(69):113858-113873. doi: 10.18632/oncotarget.23017. eCollection 2017 Dec 26.
Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies.
Carreño-Tarragona G et al.Transfus Med. 2018 Jan 25. doi: 10.1111/tme.12508. [Epub ahead of print].
Myeloma Cells are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex which Senses Lipopolysaccharide.
Kikuchi J et al. Cancer Res. 2018 Jan 23. pii: canres.2446.2017. doi: 10.1158/0008-5472.CAN-17-2446. [Epub ahead of print].
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
Breitkreutz I et al. Ann Hematol. 2018 Jan 23. doi: 10.1007/s00277-018-3237-5. [Epub ahead of print].
Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram.
Chen TC et al. Int J Mol Sci. 2018 Jan 17;19(1). pii: E277. doi: 10.3390/ijms19010277.
YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1.
Ookura M et al. Oncotarget. 2017 Dec 4;8(67):111535-111550. doi: 10.18632/oncotarget.22871. eCollection 2017 Dec 19.
Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma.
Zhan X et al. Oncotarget. 2017 Nov 27;8(67):111213-111224. doi: 10.18632/oncotarget.22740. eCollection 2017 Dec 19.
TP53 polymorphism in plasma cell myeloma.
Zmorzynski SA et al. Folia Histochem Cytobiol. 2018 Jan 15. doi: 10.5603/FHC.a2017.0022. [Epub ahead of print].
Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z et al. Bioorg Med Chem Lett. 2018 Jan 2. pii: S0960-894X(18)30002-7. doi: 10.1016/j.bmcl.2018.01.002. [Epub ahead of print].
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S et al. Br J Haematol. 2018 Jan;180(2):246-258. doi: 10.1111/bjh.15033.
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
Menssen HD et al. J Cancer Res Clin Oncol. 2018 Jan 11. doi: 10.1007/s00432-017-2564-6. [Epub ahead of print].
Modeling Multiple Myeloma-Bone Marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D et al. Haematologica. 2018 Jan 11. pii: haematol.2017.167486. doi: 10.3324/haematol.2017.167486. [Epub ahead of print].
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V et al. Leuk Lymphoma. 2018 Jan 11:1-11. doi: 10.1080/10428194.2017.1421760. [Epub ahead of print].
Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3.
Ma J et al. Tumour Biol. 2018 Jan;40(1):1010428317731369. doi: 10.1177/1010428317731369.
Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S et al. Exp Cell Res. 2018 Jan 6. pii: S0014-4827(18)30006-5. doi: 10.1016/j.yexcr.2018.01.005. [Epub ahead of print].
Multiple myeloma cells adapted to long-exposure of hypoxia exhibit stem cell characters with TGF-β/Smad pathway activation.
Nakagawa Y et al. Biochem Biophys Res Commun. 2018 Jan 6. pii: S0006-291X(18)30040-8. doi: 10.1016/j.bbrc.2018.01.034. [Epub ahead of print].
Scriptaid inhibits cell survival, cell cycle and promotes apoptosis in multiple myeloma via epigenetic regulation of p21.
Yao R et al. Exp Hematol. 2018 Jan 2. pii: S0301-472X(17)30911-6. doi: 10.1016/j.exphem.2017.12.012. [Epub ahead of print].
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in vitro and in Vivo.
Lee HY et al. J Med Chem. 2018 Jan 5. doi: 10.1021/acs.jmedchem.7b01404. [Epub ahead of print].
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.
Zahoor M et al. Blood Adv. 2017 Dec 13;1(27):2656-2666. doi: 10.1182/bloodadvances.2017010801. eCollection 2017 Dec 26.
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
Gillardin PS et al. Int J Mol Sci. 2017 Dec 23;19(1). pii: E40. doi: 10.3390/ijms19010040.
DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
Uematsu A et al. Biochem Biophys Res Commun. 2018 Jan 15;495(3):2289-2295. doi: 10.1016/j.bbrc.2017.12.142. Epub 2017 Dec 25.
Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
Huynh M et al. J Biol Chem. 2017 Dec 26. pii: jbc.RA117.000667. doi: 10.1074/jbc.RA117.000667. [Epub ahead of print].
Knockdown of long non-coding RNA H19 inhibits multiple myelomacell growth via NF-κB pathway.
Sun Y et al. Sci Rep. 2017 Dec 22;7(1):18079. doi: 10.1038/s41598-017-18056-9.
A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.
Takamatsu H et al. Br J Haematol. 2017 Dec 22. doi: 10.1111/bjh.15002. [Epub ahead of print].
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.
Drew AE et al. Sci Rep. 2017 Dec 21;7(1):17993. doi: 10.1038/s41598-017-18446-z.
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.
Zarone MR et al. Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.
Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression.
De Smedt E et al. Cancer Res. 2017 Dec 19. pii: canres.1544.2017. doi: 10.1158/0008-5472.CAN-17-1544. [Epub ahead of print].